Get started
Author

Janna Christy‐Bittel

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
2019 · Scott Kopetz, Axel Grothey, et al. · New England Journal of Medicine · 1,483
PDF
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
2021 · Josep Tabernero, Axel Grothey, et al. · Journal of Clinical Oncology · 569
PDF
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
2019 · Eric Van Cutsem, Sanne Huijberts, et al. · Journal of Clinical Oncology · 224
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
2020 · Bradley J. Monk, Rachel N. Grisham, et al. · Journal of Clinical Oncology · 155
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
2017 · Johanna C Bendell, Milind Javle, et al. · British Journal of Cancer · 127
PDF
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
2020 · Scott Kopetz, Axel Grothey, et al. · Journal of Clinical Oncology · 48
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
2012 · Richard S. Finn, Milind M. Javle, et al. · Journal of Clinical Oncology · 48
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.
2018 · Eric Van Cutsem, Pieter-Jan Cuyle, et al. · Journal of Clinical Oncology · 36
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
2018 · R. S. Finn, D. H. Ahn, et al. · Investigational New Drugs · 31
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
2020 · Scott Kopetz, Axel Grothey, et al. · Journal of Clinical Oncology · 27
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
2021 · J. Tabernero, L. Velez, et al. · ESMO Open · 26
PDF
BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
2019 · S. Kopetz, A. Grothey, et al. · Annals of Oncology · 24
PDF
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
2020 · Scott Kopetz, Axel Grothey, et al. · Journal of Clinical Oncology · 23
Multiple‐Dose, Placebo‐Controlled, Phase I Study of Oral Dolasetron
1996 · Thomas L. Hunt, Michael Cramer, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 22
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
2019 · Scott Kopetz, Axel Grothey, et al. · Journal of Clinical Oncology · 17
BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
2018 · E. Van Cutsem, P. Cuyle, et al. · Annals of Oncology · 16
The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
2014 · Bradley J. Monk, Rachel N. Grisham, et al. · Journal of Clinical Oncology · 9
The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
2015 · Bradley J. Monk, Rachel N. Grisham, et al. · Journal of Clinical Oncology · 7
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
2019 · J. Tabernero, A. Grothey, et al. · Annals of Oncology · 5
LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
2020 · A. Grothey, S. Kopetz, et al. · Annals of Oncology · 2
PDF
A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
2015 · Rachel N. Grisham, Michael S. Gordon, et al. · Journal of Clinical Oncology · 2
P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?
2005 · G. Clark, P. Cagnoni, et al. · Lung Cancer · 2
BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
2019 · Jayesh Desai, Scott Kopetz, et al. · Asia-Pacific Journal of Clinical Oncology
BRAF V600E-突然変異mCRCの日本人患者におけるENCO+BINI+CETUX:安全性導入試験からBEACON CRC研究
2019 · Hideaki Bando, Kei Muro, et al. · 日本臨床腫瘍学会学術集会(CD-ROM)
A multicenter, placebo controlled trial of continuous intravenous diltiazem infusion (IV DILT) for twenty-four hour rate control during atrial flutter/fibrillation (Af1/Afib)
1990 · Kenneth A Ellenbogen, Virgil C Dias, et al. · Journal of the American College of Cardiology
Works count: 25
Citation count: 2,901
H-index: 16
I10-index: 16
Year
Topic
Type